Literature DB >> 385922

Can postmarketing surveillance help to effect optimal drug therapy?

B L Strom, K L Melmon.   

Abstract

Postmarketing drug surveillance (PMS) assesses the epidemiology of drug use and monitors beneficial or harmful effects of drugs following marketing. If used systematically, PMS can substantially improve drug therapy in the United States. This can be accomplished by generating information on drug use and effects otherwise unavailable, by enabling a more efficient drug approval process, and by educating drug prescribers. However, to be successful, any PMS system will need a good deal of input from such prescribers.

Mesh:

Year:  1979        PMID: 385922

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

1.  First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma.

Authors:  L Blais; S Suissa; J F Boivin; P Ernst
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Development of new drugs in man: a review.

Authors:  I B Davies; I M Grind; A Pottage; P Turner
Journal:  J R Soc Med       Date:  1986-02       Impact factor: 5.344

Review 3.  Techniques of postmarketing surveillance. An overview.

Authors:  J L Carson; B L Strom
Journal:  Med Toxicol       Date:  1986 Jul-Aug

Review 4.  The way towards adverse event monitoring in clinical trials.

Authors:  M A Wallander
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

5.  Problems of post-marketing surveillance.

Authors:  W M Castle; J T Nicholls; C C Downie
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.